Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Stock Report

Market Cap: US$753.1m

Rocket Pharmaceuticals Management

Management criteria checks 3/4

Rocket Pharmaceuticals' CEO is Gaurav Shah, appointed in Jan 2018, has a tenure of 7.33 years. total yearly compensation is $6.84M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $7.21M. The average tenure of the management team and the board of directors is 4.4 years and 7.3 years respectively.

Key information

Gaurav Shah

Chief executive officer

US$6.8m

Total compensation

CEO salary percentage9.3%
CEO tenure7.3yrs
CEO ownership1.0%
Management average tenure4.4yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Apr 02
We're Keeping An Eye On Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharma Is A Buy At These Prices With Promising Data

Feb 12

Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain

Dec 02

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Sep 23
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Sep 15

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

Jun 28

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07
Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22
We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

CEO Compensation Analysis

How has Gaurav Shah's remuneration changed compared to Rocket Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$258m

Dec 31 2024US$7mUS$636k

-US$259m

Sep 30 2024n/an/a

-US$258m

Jun 30 2024n/an/a

-US$253m

Mar 31 2024n/an/a

-US$249m

Dec 31 2023US$8mUS$625k

-US$246m

Sep 30 2023n/an/a

-US$253m

Jun 30 2023n/an/a

-US$249m

Mar 31 2023n/an/a

-US$237m

Dec 31 2022US$7mUS$598k

-US$222m

Sep 30 2022n/an/a

-US$199m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$172m

Dec 31 2021US$8mUS$590k

-US$169m

Sep 30 2021n/an/a

-US$186m

Jun 30 2021n/an/a

-US$165m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$540k

-US$140m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$89m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$4mUS$480k

-US$77m

Sep 30 2019n/an/a

-US$85m

Jun 30 2019n/an/a

-US$82m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$6mUS$414k

-US$75m

Compensation vs Market: Gaurav's total compensation ($USD6.84M) is above average for companies of similar size in the US market ($USD4.00M).

Compensation vs Earnings: Gaurav's compensation has been consistent with company performance over the past year.

CEO

Gaurav Shah (49 yo)

7.3yrs

Tenure

US$6,841,407

Compensation

Dr. Gaurav D. Shah was Advisor of Genenta Science S.p.A. from July 2024 until 2025. Dr. Shah has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Execu...

Leadership Team

NamePositionTenureCompensationOwnership
Gaurav Shah
CEO & Director7.3yrsUS$6.84m0.96%
$ 7.2m
Kinnari Patel
Head of R&D7.3yrsUS$6.70m0.42%
$ 3.2m
Aaron Ondrey
Chief Financial Officer1.2yrsUS$3.10m0%
$ 0
Martin Wilson
General Counsel3.5yrsUS$2.11m0.0095%
$ 71.7k
Jonathan Schwartz
Chief Medical & Gene Therapy Officer7.3yrsUS$2.36m0.10%
$ 774.5k
Kevin Giordano
Director of Corporate Communicationsno datano datano data
Isabel Carmona
Chief People Officer3.7yrsno datano data
Gayatri Rao
Senior VP of Clinical Safety & Chief Regulatory Officer5.1yrsno datano data
Raj Prabhakar
Chief Business Officerno dataUS$2.82mno data
Sarbani Chaudhuri
Chief Commercial & Medical Affairs Officerless than a yearno datano data

4.4yrs

Average Tenure

49yo

Average Age

Experienced Management: RCKT's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gaurav Shah
CEO & Director7.3yrsUS$6.84m0.96%
$ 7.2m
David Southwell
Independent Director10.8yrsUS$404.61k0.089%
$ 671.8k
Pedro Granadillo
Independent Director7.3yrsUS$429.98k0.041%
$ 305.5k
Carsten Boess
Independent Director9.3yrsUS$429.47k0%
$ 0
G. Dolsten
Directorless than a yearUS$669.25kno data
Roderick Tze Wong
Chairman of the Board7.3yrsUS$409.98k0%
$ 0
Fady Malik
Independent Non-Executive Director3.2yrsUS$401.97k0%
$ 0
Elisabeth Bjork
Independent Director5.1yrsUS$416.93k0%
$ 0
Gotham Makker
Director7.3yrsUS$405.78k0.58%
$ 4.4m
Robert Woods
Independent Non- Executive Director1.4yrsUS$413.94k0%
$ 0
Piratip Pratumsuwan
Independent Directorless than a yearno datano data

7.3yrs

Average Tenure

58yo

Average Age

Experienced Board: RCKT's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 16:35
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity